Viatris Wins U.S. FDA Approval for Gwyn Lo Contraceptive
PITTSBURGH, July 29, 2026 Viatris Inc. has received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo™ (norelgestromin...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PITTSBURGH, July 29, 2026 Viatris Inc. has received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo™ (norelgestromin...
Mumbai, India and Naples, Florida, June 5, 2026 Global pharmaceutical company Lupin Limited has secured a major regulatory milestone...
MUMBAI, India and NAPLES, Fla., May 13, 2026 Global pharmaceutical company Lupin Limited announced that it has received approval...
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....
September 3, 2025 – Mumbai & Naples – Lupin Limited announced U.S. FDA approval for its Risperidone extended-release injectable...
